This study is testing a drug called Eloralintide (LY3841136) to see if it is safe and effective for people with moderate-to-severe obstructive sleep apnea (OSA) and who are also obese or overweight. OSA is a condition where breathing repeatedly stops and starts during sleep. You might be able to join if you have confirmed OSA, a specific score on a sleep test (Apnea-Hypopnea Index or AHI), and a certain body mass index (BMI). The study will look at how much your body weight changes and how your AHI changes over 64 weeks. This study is currently unclear about its recruitment status and plans to enroll about 800 participants. Some participants may be using a breathing machine called PAP therapy, while others may not be able to or choose not to use it.

Study design

This interventional study is designed to evaluate Eloralintide versus a placebo (an inactive substance) in about 800 participants. It includes two independent studies based on whether participants use PAP therapy.

What's involved

Participation in the study will last about 76 weeks. You would receive either Eloralintide or a placebo, both administered as an injection under the skin (SC).

Compensation

Not stated in the trial record.

Follow-up

The primary outcomes, body weight and Apnea-Hypopnea Index (AHI), will be measured at Baseline and Week 64.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.